Trials / Unknown
UnknownNCT02852850
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-06-01
- First posted
- 2016-08-02
- Last updated
- 2016-10-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02852850. Inclusion in this directory is not an endorsement.